/STTK
STTK Stock - Shattuck Labs, Inc.
Healthcare|BiotechnologyNASDAQ
$3.15+6.42%
+$0.19 (+6.42%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.52
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+90.5%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for STTK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.12 – $3.18
TARGET (TP)$6.00
STOP LOSS$2.90
RISK/REWARD1:11.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.71
52W High$3.38
52W Low$0.69
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.72M | $1.66M | $652,000 | $30.02M | $9.93M |
| Gross Profit | $5.72M | $-2,385,000 | $652,000 | $28.64M | $-27,549,000 |
| Gross Margin | 100.0% | -143.9% | 100.0% | 95.4% | -277.3% |
| Operating Income | $-80,567,000 | $-91,957,000 | $-103,329,000 | $-45,269,000 | $-36,931,000 |
| Net Income | $-75,410,000 | $-87,298,000 | $-101,945,000 | $-44,974,000 | $-36,603,000 |
| Net Margin | -1318.1% | -5268.4% | -15635.7% | -149.8% | -368.5% |
| EPS | $-1.49 | $-2.05 | $-2.41 | $-1.07 | $-0.88 |
Company Overview
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
60%
Hold / Neutral
4
40%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
6 Bullish4 Neutral/Bearish
Price Targets
$10
Average Target
↑ 212.9% Upside
Now
$2
Low
$10
Average
$28
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 1st 2025 | H.C. Wainwright | Upgrade | Buy | $6 |
| September 8th 2025 | Wedbush | Initiation | Outperform | $4 |
| March 17th 2025 | Leerink Partners | Initiation | Outperform | $4 |
| October 2nd 2024 | Citigroup | Downgrade | Neutral | $2← $8 |
| October 2nd 2024 | Needham | Downgrade | Hold | - |
| October 1st 2024 | H.C. Wainwright | Downgrade | Neutral | - |
| June 17th 2024 | BTIG Research | Downgrade | Neutral | - |
| August 31st 2022 | BTIG Research | Initiation | Buy | $12 |
| June 1st 2022 | Citigroup | Initiation | Buy | $13 |
| May 2nd 2022 | H.C. Wainwright | Initiation | Buy | $28 |
Earnings History & Surprises
STTKBeat Rate
74%
Last 19 quarters
Avg Surprise
+10.3%
EPS vs Estimate
Beats / Misses
14/5
Last 12 quarters
Latest EPS
$-0.14
Q4 2025
EPS Surprise History
Q1 24
+19.6%
$-0.41vs$-0.51
Q2 24
+21.3%
$-0.37vs$-0.47
Q3 24
-2.4%
$-0.42vs$-0.41
Q4 24
+19.5%
$-0.33vs$-0.41
Q1 25
+2.6%
$-0.37vs$-0.38
Q2 25
+6.9%
$-0.27vs$-0.29
Q3 25
+4.0%
$-0.24vs$-0.25
Q4 25
+6.7%
$-0.14vs$-0.15
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.12 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.15 | $-0.14 | +6.7% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.25 | $-0.24 | +4.0% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-0.29 | $-0.27 | +6.9% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.38 | $-0.37 | +2.6% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.41 | $-0.33 | +19.5% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.41 | $-0.42 | -2.4% | ✗ MISS |
Q2 2024 | May 2, 2024 | $-0.47 | $-0.37 | +21.3% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.51 | $-0.41 | +19.6% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.52 | $-0.65 | -25.0% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.52 | $-0.50 | +3.8% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.61 | $-0.49 | +19.7% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-0.62 | $-0.60 | +3.2% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.68 | $-0.58 | +14.7% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.61 | $-0.65 | -6.6% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.55 | $-0.58 | -5.5% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $-0.43 | $0.18 | +141.9% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.44 | $-0.41 | +6.8% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.34 | $-0.56 | -64.7% | ✗ MISS |
Q2 2021 | May 10, 2021 | $-0.39 | $-0.28 | +28.2% | ✓ BEAT |
Latest News
Shattuck Labs shares are trading higher after HC Wainwright & Co upgraded the stock from Neutral to Buy and announced a $6 price target.
📈 PositiveBenzinga•Dec 1, 2025, 05:01 PM
HC Wainwright & Co. Upgrades Shattuck Labs to Buy, Announces $6 Price Target
📈 PositiveBenzinga•Dec 1, 2025, 12:18 PM
Shattuck Labs Q3 EPS $(0.14), Inline, Sales $1.000M Down From $2.997M YoY, Cash Balance Of $86.1M Expected To Provide Cash Runway Into 2029
➖ NeutralBenzinga•Nov 6, 2025, 09:59 PM
Shattuck Labs shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced $4 price target.
📈 PositiveBenzinga•Sep 8, 2025, 04:06 PM
Wedbush Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $4
📈 PositiveBenzinga•Sep 8, 2025, 01:07 PM
Shattuck Labs Closes Up To $103M Private Placement To Fund SL-325 Through Phase 2 Trials, Extends Cash Runway Into 2029; Company Appoints Dan Baker M.D. And OrbiMed's Mona Ashiya Ph.D.
📈 PositiveBenzinga•Aug 26, 2025, 10:39 AM
Shattuck Labs IND For SL-325 Now In Effect; Preclinical Data Shows High-Affinity DR3 Binding And Favorable Safety Profile
📈 PositiveBenzinga•Aug 21, 2025, 02:19 PM
Shattuck Labs Narrows Loss in Fiscal Q2
📈 PositiveThe Motley Fool•Aug 14, 2025, 10:46 AM
Frequently Asked Questions about STTK
What is STTK's current stock price?
Shattuck Labs, Inc. (STTK) is currently trading at $3.15 per share. The stock has moved +6.42% today.
What is the analyst price target for STTK?
The average analyst price target for STTK is $6.00, based on 1 analyst.
What sector is Shattuck Labs, Inc. in?
Shattuck Labs, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is STTK's market cap?
Shattuck Labs, Inc. has a market capitalization of $0.15 billion, making it a small-cap company.
Does STTK pay dividends?
No, Shattuck Labs, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARTV
Artiva Biotherapeutics, Inc.
$4.74
Mkt Cap: $0.1B
CNTB
Connect Biopharma Holdings Limited
$2.27
Mkt Cap: $0.1B
CNTX
Context Therapeutics Inc.
$1.27
Mkt Cap: $0.1B
IFRX
InflaRx N.V.
$1.11
Mkt Cap: $0.1B
IMA
ImageneBio Inc
$6.18
Mkt Cap: $0.1B
KLRS
Kalaris Therapeutics Inc
$9.13
Mkt Cap: $0.2B
MGX
Metagenomi, Inc. Common Stock
$1.76
Mkt Cap: $0.1B
OVID
Ovid Therapeutics Inc.
$1.47
Mkt Cap: $0.1B
STRO
Sutro Biopharma, Inc.
$9.98
Mkt Cap: $0.1B
ZNTL
Zentalis Pharmaceuticals, Inc.
$1.40
Mkt Cap: $0.1B
Explore stocks similar to STTK for comparison